A DVANCES in the characterization of pituitary tumors have been dependent upon the development of techniques for defining the cell types as well as the hormone products of these tumors. The development of the radioimmunoassay for prolactin (PRL), for example, has led to the recognition that many apparently nonfunctioning adenomas produced PRL. About 30% of pituitary adenomas in pathology and endocrinology series still appear to have no clinical evidence of hormonal hypersecretion. 13.~,26,~7 This paper presents immunocytochemical data suggesting that many of these tumors produce subunits of glycoprotein hormones which are endocrinologically inactive.
The glycoprotein hormones include follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), and the placental hormone chorionic gonadotropin (CG). They contain two subunits: the alpha subunit which is common to each of them, and a beta subunit (/3-FSH,/3-LH,/3-TSH, and 13-CG) which confers biological and immunological specificity. 44 Glycoprotein hormone-secreting pituitary tumors are unusual; however, a small percentage of apparently nonfunctioning tumors secrete the biologically inactive alpha subunit. 21,z5,45 From the data presented here it appears that a substantial number also contain beta subunits alone or in combination with the alpha subunit.
Clinical Material and Methods
Thirty-seven patients diagnosed from preoperative 300-1000 * PRL = prolactin; TSH = thyroid-stimulating hormone; FSH = follicle-stimulating hormone; LH = luteinizing hormone; --= data unavailable.
clinical evaluation as having "nonfunctioning" pituitary adenomas underwent transsphenoidal surgery for masses within the sella turcica. At surgery, fragments of tumor were taken from each patient to be fixed in 10% formalin and embedded in paraffin for sectioning and immunocytochemical staining. Each tumor was stained for the following pituitary peptides: PRL, human growth hormone (GH), adrenocorticotropic hormone (ACTH), the beta subunits of FSH, LH, and TSH, and the common alpha subunit of the glycoprotein hormones.
Immunocytochemical staining was carried out on 5-um paraffin-embedded sections of each tumor, using either a modified Sternberger's peroxidase-antiperoxidase (PAP) technique 53 or the avidin-biotin-peroxidase complex (ABC) techniquefl ~ Antisera* were used at the following dilutions for the PAP technique: anti-PRL at 1:750, anti-GH at 1:750, anti-/3-TSH at 1:500, anti-B-FSH at 1:200, and anti-/3-LH at 1:250. For the ABC technique, the following dilutions of antisera were used: anti-PRL at 1:1500, anti-GH at 1:1500, anti-ACTH at 1:400, anti-/3-TSH at 1:1000, anti-/3-FSH at 1:400, and anti-/3-LH at 1:500. For the alpha subunit, a monoclonal antibody raised against the alpha subunit of human CG prepared in the neuroendocrinology laboratory by one of us (E.C.R.) was also used, at a dilution of 1:100 of the mouse ascites fluid. The duration of the incubation with the primary antibody was 45 minutes at room temperature. The antigen-antibody binding was visualized with 3,3'-diaminobenzidine/H2Oz incuba-* The antisera against PRL, GH,/3-TSH, B-FSH, r and the alpha subunit of TSH were obtained from Dr. S. Raiti of the National Pituitary Agency, Baltimore, Maryland; anti-ACTH was supplied by Immuno Nuclear Corp., Stillwater, Minnesota.
tion. The negative control sections were incubated with normal rabbit serum in place of the primary antisera. For positive controls, sections from normal human pituitary gland obtained at autopsy were incubated along with each tumor specimen. The extent of immunoreactivity was recorded for each hormone on a scale from "-" (no staining) to "++++" (heavy staining).
Preoperative serum hormonal values of the intact hormones and the alpha subunit were available in 27 of the 37 patients using well-established assay methods for PRL, 8 TSH, 45 LH, 4~ FSH, 7 and the alpha subunit. 46 To form correlations with clinical endocrine data, the charts were reviewed to establish patients' age, sex, presenting complaint, visual acuity status, and plasma levels of PRL, GH, TSH, FSH, LH, the alpha subunit, and testosterone.
Results
Sixteen men aged 43 to 71 years (median age 54 years) and 21 women aged 26 to 75 years (median age 55.5 years) with clinically nonfunctioning pituitary adenomas were included in this study. Loss of vision was the major presenting symptom, affecting 61% of women and 70% of men. Diminished libido was found in 15% of women and 40% of men. Other less frequent complaints were diplopia (4%) and headache (8%). Sixty-nine percent of patients had a bitemporal hemianopsia on visual-field testing; other visual findings included a central scotoma in one patient and a left abducens palsy in another. Twenty percent of patients had a normal neuro-ophthalmological examination.
Preoperative endocrine data are presented in detail in Tables 1 and 2 . None of these patients had clinical or laboratory evidence suggesting acromegaly or Cush- ing's syndrome. Seventy percent of the men had PRL levels above 10 ng/ml and 65 % of the women had levels above 15 ng/ml, presently considered the upper limits of normal. In none was the level greater than 50 ng/ ml. Ten percent of women and 38% of men had an elevated alpha subunit level in their plasma. Ninety percent of the men with these tumors had decreased testosterone levels; 90% of the women who were over 50 years of age did not have the expected elevation of gonadotropins found in postmenopausal women. None of the patients were thyrotoxic or had inappropriately elevated TSH levels, findings that would have suggested TSH production by the pituitary adenoma. In one man (Case 13), presumed to have a nonfunctioning tumor based upon previous endocrine studies, elevated preoperative levels of testosterone and LH returned to normal following surgery. Although his LH and testosterone levels were variable, these data are consistent with an LH-secreting adenoma. None of the premenopausal women and none of the men had elevated FSH levels suggestive of an FSH-producing tumor.
The immunohistochemical staining data are presented in detail in Tables 3 and 4 . A typical example of moderate staining is shown in Fig. t . Seventy-three percent of tumors had positive staining for one or more hormones: 27% had one or more beta subunits without alpha, 37.9% had both alpha and beta subunits, and P. McL. Black, et al. 5.4% stained only for ACTH. Table 5 summarizes the identifiable hormone products found by immunocytochemistry in these tumors: /3-FSH was most common (60%), with /3-LH and /3-TSH found in roughly half and one-third of tumors, respectively. The alpha subunit, alone or in combination, was identified in 40.5% of these tumors. In less than one-third of cases no hormone or subunit was identified.
Discussion
Approximately 30% of pituitary adenomas are currently thought to be clinically nonfunctioning. 2'13'14 '48,57 In the present series 37 (23%) of 160 cases were found to be in that category. Based on immunocytochemical analyses for detecting PRL, ACTH, GH, LH, FSH, and TSH, different surgical series have reported the percentage of adenomas without apparent products as 25.5%, 48 34%, 37 and 40%. 14 From the present series, a typical clinical syndrome can be described for the patient harboring a "nonfunctioning" tumor. The lesion is usually large enough to produce subjective and objective loss of vision and often diminished libido. Most of these tumors occur in patients over 50 years of age. Gonadotropin function is impaired in most patients: men have low serum testosterone concentrations and women have relatively low gonadotropin levels. In most patients immunoassayable FSH, LH, and TSH are not elevated, and the level of alpha subunit is elevated in less than 10% of patients. Prolactin is elevated in most patients (70% in our series) but not beyond 50 ng/ml, suggesting that the PRL elevation is not the result of PRL secretion from the Multiple hormones were found in some tumors.
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t h e b e t a s u b u n i t c a n b e f o u n d i n n o r m a l p i t u i t a r y in m o r e cells t h a n t h e a l p h a . H y p e r s e c r e t i o n o f t h e a l p h a s u b u n i t h a s b e e n well e s t a b l i s h e d as a n u n c o m m o n b u t c o n s i s t e n t p h e n o m e n o n o c c u r r i n g in 1% to 10% o f adenomas. 21, [23] [24] [25] 34 to cross-reactivity of uncombined /3-LH subunit with antisera for intact LH. However, because uncombined ~-LH subunit is not biologically active, testosterone levels are reduced. These findings may account for the large numbers of hypogonadal males in this series despite normal levels of gonadotropins.
Several Esiri, et al., found this in 40% of cases. The striking finding of the present series, however, is the fact that a large number of clinically silent adenomas stained for the beta subunits of TSH, LH, or FSH. It is known that, to be endocrinologically active, the beta subunit must be combined with the alpha subunit; 44 these tumors may, therefore, be producing uncombined subunits that are hormonally inactive, a hypothesis supported by Snyder, et al. 5~ To prove this, however, would require the use of an antibody that identifies the whole hormone immunocytochemically and could be compared with antibody identifying only fragments.
The observation that glycoprotein hormone fragments are found in nonfunctioning tumors may help to explain the fact that many of these tumors do in fact have secretory granules. More importantly, it may have significant therapeutic implications as well. Plasma FSH concentrations have been shown to decrease with administration of bromocriptine to a patient with an FSH-secreting adenoma. 4 There is also preliminary experimental evidence that hormonal manipulation may decrease growth in pituitary tumors in rats. 12,31 Hormonal manipulation may therefore be possible as ad-P. McL. Black, et al. junctive treatment in these apparently "nonfunctioning" adenomas, potentially allowing novel therapeutic approaches to their long-term control.
